M.D. Anderson Cancer Center
The goal of this clinical research study is to learn about the safety and effects of BMS-986504 in combination with olaparib in patients with advanced solid tumors with MTAP loss.
Primary Objective: 1\. To determine the safety and tolerability of BMS-986504 in combination with olaparib in patients with advanced solid tumors with MTAP loss. Secondary Objectives: 1. To characterize the PK profile of BMS-986504 in combination with olaparib in patients with advanced solid tumors with MTAP loss. 2. To determine the preliminary antitumor activity of BMS-986504 in combination with olaparib with advanced solid tumors with MTAP loss. 3. To evaluate the pharmacodynamic activity of BMS-986504 in combination with olaparib in advanced solid tumors with MTAP loss. 4. To evaluate p…
Inclusion Criteria: 1. Age ≥18 years. 2. All patients must have a histologically confirmed advanced or metastatic solid tumor that has been refractory to standard therapy or are not eligible for standard therapy and have no alternative curative-intent treatment options at the time of patient enrollment. For the dose escalation, any solid tumor is eligible, but enrollment will be enriched for CCA and pancreatic cancer. For the pharmacodynamic expansion, patients must have histologically confirmed advanced or metastatic CCA or pancreatic cancer. 3. Homozygous deletion of MTAP as detected by Cli…
Given by mouth
Given by mouth
Arctuva estimate
Verify or correct the compensation shown for this listing.